pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·15m ago·1 min read
save

Lilly pens another deal, inking up to $5.9B oncology pact with Stipple

Nov 17, 2026·read at BioSpace ↗

A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.

source

Reporting by BioSpace.

read at BioSpace ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoGenetix’s genetic medicines are officially profitable, with $327M in sales YTDBioSpace
  • 2h agoMarrow Therapeutics debuts with $173M to tackle blood disorders in vivoBioSpace
  • 9h agoBiotech’s boardroom gains for women fail to translate to CEO rolesBioSpace
  • 20h agoAstraZeneca, Calidi, Tempest make significant workforce cutsBioSpace
  • 22h agoSerious adverse events mar robust efficacy data for Helus’ psychedelic in major depressionBioSpace